Selected research
Market Analysis & Forecast
Global Veterinary Drugs Market Analysis and Forecast 2026-2032
Market perspective
The global Veterinary Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Veterinary Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Veterinary Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Veterinary Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Veterinary Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Veterinary Drugs include Zoetis Inc., Merck Animal Health, Bayer AG, Virbac SA, Vetoquinol SA, IDEXX Laboratories, Inc., Elanco, Covetrus, Inc. and Ceva Sante Animale S.A., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Veterinary Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Veterinary Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Veterinary Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Veterinary Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Veterinary Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Veterinary Drugs revenue, projected growth trends, production technology, application and end-user industry.
Veterinary Drugs Segment by Company
Zoetis Inc.
Merck Animal Health
Bayer AG
Virbac SA
Vetoquinol SA
IDEXX Laboratories, Inc.
Elanco
Covetrus, Inc.
Ceva Sante Animale S.A.
Boehringer Ingelheim Animal Health
Veterinary Drugs Segment by Type
Treatment Drugs
Vaccines
Others
Veterinary Drugs Segment by Application
Chickens
Cattle
Swine
Others
Veterinary Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Veterinary Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Veterinary Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Veterinary Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Veterinary Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Veterinary Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Veterinary Drugs revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Treatment Drugs
- Vaccines
- Others
Applications
- Chickens
- Cattle
- Swine
- Others
Companies covered
- Zoetis Inc.
- Merck Animal Health
- Bayer AG
- Virbac SA
- Vetoquinol SA
- IDEXX Laboratories, Inc.
- Elanco
- Covetrus, Inc.
- Ceva Sante Animale S.A.
- Boehringer Ingelheim Animal Health
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Veterinary Drugs Market by Type
- 1.2.1 Global Veterinary Drugs Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Treatment Drugs
- 1.2.3 Vaccines
- 1.2.4 Others
- 1.3 Veterinary Drugs Market by Application
- 1.3.1 Global Veterinary Drugs Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Chickens
- 1.3.3 Cattle
- 1.3.4 Swine
- 1.3.5 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Veterinary Drugs Market Dynamics
- 2.1 Veterinary Drugs Industry Trends
- 2.2 Veterinary Drugs Industry Drivers
- 2.3 Veterinary Drugs Industry Opportunities and Challenges
- 2.4 Veterinary Drugs Industry Restraints
3 Global Growth Perspective
- 3.1 Global Veterinary Drugs Market Perspective (2021-2032)
- 3.2 Global Veterinary Drugs Growth Trends by Region
- 3.2.1 Global Veterinary Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Veterinary Drugs Market Size by Region (2021-2026)
- 3.2.3 Global Veterinary Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Veterinary Drugs Revenue by Players
- 4.1.1 Global Veterinary Drugs Revenue by Players (2021-2026)
- 4.1.2 Global Veterinary Drugs Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Veterinary Drugs Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Veterinary Drugs Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Veterinary Drugs Key Players Headquarters & Area Served
- 4.4 Global Veterinary Drugs Players, Product Type & Application
- 4.5 Global Veterinary Drugs Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Veterinary Drugs Market CR5 and HHI
- 4.6.3 2025 Veterinary Drugs Tier 1, Tier 2, and Tier 3
5 Veterinary Drugs Market Size by Type
- 5.1 Global Veterinary Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Veterinary Drugs Revenue by Type (2021-2032)
- 5.3 Global Veterinary Drugs Revenue Market Share by Type (2021-2032)
6 Veterinary Drugs Market Size by Application
- 6.1 Global Veterinary Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Veterinary Drugs Revenue by Application (2021-2032)
- 6.3 Global Veterinary Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Zoetis Inc.
- 7.1.1 Zoetis Inc. Company Information
- 7.1.2 Zoetis Inc. Business Overview
- 7.1.3 Zoetis Inc. Veterinary Drugs Revenue and Gross Margin (2021-2026)
- 7.1.4 Zoetis Inc. Veterinary Drugs Product Portfolio
- 7.1.5 Zoetis Inc. Recent Developments
- 7.2 Merck Animal Health
- 7.2.1 Merck Animal Health Company Information
- 7.2.2 Merck Animal Health Business Overview
- 7.2.3 Merck Animal Health Veterinary Drugs Revenue and Gross Margin (2021-2026)
- 7.2.4 Merck Animal Health Veterinary Drugs Product Portfolio
- 7.2.5 Merck Animal Health Recent Developments
- 7.3 Bayer AG
- 7.3.1 Bayer AG Company Information
- 7.3.2 Bayer AG Business Overview
- 7.3.3 Bayer AG Veterinary Drugs Revenue and Gross Margin (2021-2026)
- 7.3.4 Bayer AG Veterinary Drugs Product Portfolio
- 7.3.5 Bayer AG Recent Developments
- 7.4 Virbac SA
- 7.4.1 Virbac SA Company Information
- 7.4.2 Virbac SA Business Overview
- 7.4.3 Virbac SA Veterinary Drugs Revenue and Gross Margin (2021-2026)
- 7.4.4 Virbac SA Veterinary Drugs Product Portfolio
- 7.4.5 Virbac SA Recent Developments
- 7.5 Vetoquinol SA
- 7.5.1 Vetoquinol SA Company Information
- 7.5.2 Vetoquinol SA Business Overview
- 7.5.3 Vetoquinol SA Veterinary Drugs Revenue and Gross Margin (2021-2026)
- 7.5.4 Vetoquinol SA Veterinary Drugs Product Portfolio
- 7.5.5 Vetoquinol SA Recent Developments
- 7.6 IDEXX Laboratories, Inc.
- 7.6.1 IDEXX Laboratories, Inc. Company Information
- 7.6.2 IDEXX Laboratories, Inc. Business Overview
- 7.6.3 IDEXX Laboratories, Inc. Veterinary Drugs Revenue and Gross Margin (2021-2026)
- 7.6.4 IDEXX Laboratories, Inc. Veterinary Drugs Product Portfolio
- 7.6.5 IDEXX Laboratories, Inc. Recent Developments
- 7.7 Elanco
- 7.7.1 Elanco Company Information
- 7.7.2 Elanco Business Overview
- 7.7.3 Elanco Veterinary Drugs Revenue and Gross Margin (2021-2026)
- 7.7.4 Elanco Veterinary Drugs Product Portfolio
- 7.7.5 Elanco Recent Developments
- 7.8 Covetrus, Inc.
- 7.8.1 Covetrus, Inc. Company Information
- 7.8.2 Covetrus, Inc. Business Overview
- 7.8.3 Covetrus, Inc. Veterinary Drugs Revenue and Gross Margin (2021-2026)
- 7.8.4 Covetrus, Inc. Veterinary Drugs Product Portfolio
- 7.8.5 Covetrus, Inc. Recent Developments
- 7.9 Ceva Sante Animale S.A.
- 7.9.1 Ceva Sante Animale S.A. Company Information
- 7.9.2 Ceva Sante Animale S.A. Business Overview
- 7.9.3 Ceva Sante Animale S.A. Veterinary Drugs Revenue and Gross Margin (2021-2026)
- 7.9.4 Ceva Sante Animale S.A. Veterinary Drugs Product Portfolio
- 7.9.5 Ceva Sante Animale S.A. Recent Developments
- 7.10 Boehringer Ingelheim Animal Health
- 7.10.1 Boehringer Ingelheim Animal Health Company Information
- 7.10.2 Boehringer Ingelheim Animal Health Business Overview
- 7.10.3 Boehringer Ingelheim Animal Health Veterinary Drugs Revenue and Gross Margin (2021-2026)
- 7.10.4 Boehringer Ingelheim Animal Health Veterinary Drugs Product Portfolio
- 7.10.5 Boehringer Ingelheim Animal Health Recent Developments
8 North America
- 8.1 North America Veterinary Drugs Revenue (2021-2032)
- 8.2 North America Veterinary Drugs Revenue by Type (2021-2032)
- 8.2.1 North America Veterinary Drugs Revenue by Type (2021-2026)
- 8.2.2 North America Veterinary Drugs Revenue by Type (2027-2032)
- 8.3 North America Veterinary Drugs Revenue Share by Type (2021-2032)
- 8.4 North America Veterinary Drugs Revenue by Application (2021-2032)
- 8.4.1 North America Veterinary Drugs Revenue by Application (2021-2026)
- 8.4.2 North America Veterinary Drugs Revenue by Application (2027-2032)
- 8.5 North America Veterinary Drugs Revenue Share by Application (2021-2032)
- 8.6 North America Veterinary Drugs Revenue by Country
- 8.6.1 North America Veterinary Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Veterinary Drugs Revenue by Country (2021-2026)
- 8.6.3 North America Veterinary Drugs Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Veterinary Drugs Revenue (2021-2032)
- 9.2 Europe Veterinary Drugs Revenue by Type (2021-2032)
- 9.2.1 Europe Veterinary Drugs Revenue by Type (2021-2026)
- 9.2.2 Europe Veterinary Drugs Revenue by Type (2027-2032)
- 9.3 Europe Veterinary Drugs Revenue Share by Type (2021-2032)
- 9.4 Europe Veterinary Drugs Revenue by Application (2021-2032)
- 9.4.1 Europe Veterinary Drugs Revenue by Application (2021-2026)
- 9.4.2 Europe Veterinary Drugs Revenue by Application (2027-2032)
- 9.5 Europe Veterinary Drugs Revenue Share by Application (2021-2032)
- 9.6 Europe Veterinary Drugs Revenue by Country
- 9.6.1 Europe Veterinary Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Veterinary Drugs Revenue by Country (2021-2026)
- 9.6.3 Europe Veterinary Drugs Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Veterinary Drugs Revenue (2021-2032)
- 10.2 China Veterinary Drugs Revenue by Type (2021-2032)
- 10.2.1 China Veterinary Drugs Revenue by Type (2021-2026)
- 10.2.2 China Veterinary Drugs Revenue by Type (2027-2032)
- 10.3 China Veterinary Drugs Revenue Share by Type (2021-2032)
- 10.4 China Veterinary Drugs Revenue by Application (2021-2032)
- 10.4.1 China Veterinary Drugs Revenue by Application (2021-2026)
- 10.4.2 China Veterinary Drugs Revenue by Application (2027-2032)
- 10.5 China Veterinary Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Veterinary Drugs Revenue (2021-2032)
- 11.2 Asia Veterinary Drugs Revenue by Type (2021-2032)
- 11.2.1 Asia Veterinary Drugs Revenue by Type (2021-2026)
- 11.2.2 Asia Veterinary Drugs Revenue by Type (2027-2032)
- 11.3 Asia Veterinary Drugs Revenue Share by Type (2021-2032)
- 11.4 Asia Veterinary Drugs Revenue by Application (2021-2032)
- 11.4.1 Asia Veterinary Drugs Revenue by Application (2021-2026)
- 11.4.2 Asia Veterinary Drugs Revenue by Application (2027-2032)
- 11.5 Asia Veterinary Drugs Revenue Share by Application (2021-2032)
- 11.6 Asia Veterinary Drugs Revenue by Country
- 11.6.1 Asia Veterinary Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Veterinary Drugs Revenue by Country (2021-2026)
- 11.6.3 Asia Veterinary Drugs Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Veterinary Drugs Revenue (2021-2032)
- 12.2 SAMEA Veterinary Drugs Revenue by Type (2021-2032)
- 12.2.1 SAMEA Veterinary Drugs Revenue by Type (2021-2026)
- 12.2.2 SAMEA Veterinary Drugs Revenue by Type (2027-2032)
- 12.3 SAMEA Veterinary Drugs Revenue Share by Type (2021-2032)
- 12.4 SAMEA Veterinary Drugs Revenue by Application (2021-2032)
- 12.4.1 SAMEA Veterinary Drugs Revenue by Application (2021-2026)
- 12.4.2 SAMEA Veterinary Drugs Revenue by Application (2027-2032)
- 12.5 SAMEA Veterinary Drugs Revenue Share by Application (2021-2032)
- 12.6 SAMEA Veterinary Drugs Revenue by Country
- 12.6.1 SAMEA Veterinary Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Veterinary Drugs Revenue by Country (2021-2026)
- 12.6.3 SAMEA Veterinary Drugs Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst